Phase 1 PK and safety study of LY4065967 with and without rosuvastatin in healthy Japanese adults

Phase 1, randomised, double-blind trial of LY4065967 (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to study drug - Part A, Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to study drug - Part B and 2 more. Started Oct 2024; status: completed.